1. Home
  2. Resources
  3. Monoclonal Antibody Therapeutic Treatment

Emergency Use Authorizations

FDA Emergency Use Authorizations

Fully FDA Approved

Fully FDA Approved



The monoclonal antibody therapeutics (mAb) continue to be available for ordering and can be used to treat eligible non-hospitalized patients who have tested positive for COVID-19 and have mild to moderate symptoms. These treatments mimic your immune system’s response to SARS-CoV-2 (the infection that causes COVID-19) and are available to eligible patients 12 years and older with a high risk of progressing to severe forms of COVID-19 or being hospitalized. HHS/ASPR has an ample supply of all COVID-19 monoclonal antibody therapeutic products and we are encouraging state and territorial health departments; as well as, healthcare providers to continue ordering and using these products.

Pause in the distribution of bamlanivimab/etesevimab

In June, ASPR has paused all distribution of bamlanivimab/etesevimab together and etesevimab alone on a national basis until further notice. In addition, FDA recommends that health care providers nationwide use alternative authorized monoclonal antibody therapies, REGEN-COV (casirivimab and imdevimab) and sotrovimab, and not use bamlanivimab/etesevimab administered together at this time.

  • REGEN-COV (casirivimab and imdevimab) can be ordered directly from Amerisource Bergen
  • Sotrovimab can be ordered via GlaxoSmithKline’s website: https://www.sotrovimab.com/